

## HPBMC Human Peripheral Blood Mononuclear Cells, cryopreserved Cell Specification // Certificate of Analysis

Lot HPBMC 210303-2

Batch Release: May 12, 2021

Freshly isolated human peripheral blood mononuclear cells (PBMC) from healthy donors were purified by density gradient centrifugation using Ficoll<sup>®</sup>.

Cryopreserved cells were thawed. Cell number and viability were determined by Trypan blue exclusion staining. Subpopulations were identified by flow cytometry.

### Donor demographics and lot specific information

Gender	Age	Ethnicity	Anticoagulant	
Male	54 years	Caucasian	CPD (Citrate-Phosphate-Dextrose)	

#### Serology Testing

Donor has been screened and **tested negative** for:

- Hepatitis B (HBV-DNA, HBsAg, anti-HBc)
- Hepatitis C (HCV-RNA, anti-HCV)
- Human Immunodeficiency Virus (HIV-1-RNA, HIV)
- Hepatitis E Virus (HEV-RNA)
- Syphilis

Donor has been screened and **tested reactive** for:

• Cytomegalovirus (anti-CMV)


Cryopreservation:	Thawing: n=1
Date: March 03, 2021	Post-thaw viability: 82.5 %
Amount per vial: 45.0 x 10 <sup>6</sup> cells	Post-thaw yield per vial: 27.1 x 10 <sup>6</sup> cells Recovery: 60.3 %

### Analysis of PBMC subpopulations by flow cytometry:

#### **Surface Marker Summary**

CD19 <sup>+</sup>	CD3 <sup>+</sup>	CD3 <sup>+</sup> CD4 <sup>+</sup>	CD3 <sup>+</sup> CD8 <sup>+</sup>	CD56+
B cells	T cells	T cells	T cells	NK cells
11.1 %	80.0 %	41.8 %	34.0 %	9.9 %





# Store at -150 °C or in the vapour phase of LN<sub>2</sub>

This product should be considered as potential biohazard. Only intended for *in vitro* use. Not intended for therapeutic use.

**Note:** Yield, viability and recovery were performed at PRIMACYT using PRIMACYT's manual for thawing of primary cryopreserved PMBCs.

Issued by: T.Krimmling

Verified by: A. Ullrich